Home > Insider Trading > Filing (0001735276-24-000104)

Filing Details

Accession Number:: 0001735276-24-000104
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-11-27 17:20:36
Reporting Period:: 2024-11-25

Accepted Time:: 2024-11-27 17:20:36
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1178670	Alnylam Pharmaceuticals Inc.	ALNY	Pharmaceutical Preparations (2834)	770602661

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1886431	Joseph Kevin Fitzgerald	675 West Kendall Street Henri A. Termeer Square Cambridge MA 02142	Cso & Evp, Head Of Research	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2024-11-25	3,000	$0.00	15,881	No	4	A	Direct
Common Stock	Disposition	2024-11-26	26	$247.77	15,855	No	4	S	Direct
Common Stock	Disposition	2024-11-26	215	$249.60	15,640	No	4	S	Direct
Common Stock	Disposition	2024-11-26	318	$250.68	15,322	No	4	S	Direct
Common Stock	Disposition	2024-11-26	826	$251.42	14,496	No	4	S	Direct
Common Stock	Disposition	2024-11-26	84	$252.27	14,412	No	4	S	Direct
Common Stock	Disposition	2024-11-27	210	$250.45	14,202	No	4	S	Direct
Common Stock	Disposition	2024-11-27	851	$251.98	13,351	No	4	S	Direct
Common Stock	Disposition	2024-11-27	360	$253.44	12,991	No	4	S	Direct
Common Stock	Disposition	2024-11-27	110	$254.48	12,881	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	537	Indirect	by Managed Account

Footnotes

On February 27, 2023, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of one-third of the shares subject to the PSU based on the issuer publicly reporting FDA acceptance of a new drug application submitted for regulatory approval for a therapeutic to treat ATTR amyloidosis with cardiomyopathy after receipt of a positive, statistically significant result on a clinical outcomes endpoint from a Phase 3 study, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on November 22, 2024.
Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $247.76 to $248.67. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $249.00 to $250.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $250.05 to $251.05. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $251.07 to $252.06. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $252.09 to $252.47. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2024.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $250.27 to $250.62. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $251.76 to $252.49. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $253.07 to $254.06. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.